IRIS
GERRATANA, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.643
EU - Europa 822
AS - Asia 411
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 2
Totale 5.890
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.634
IT - Italia 265
UA - Ucraina 167
CN - Cina 155
DE - Germania 106
IE - Irlanda 77
SG - Singapore 75
IN - India 69
VN - Vietnam 64
SE - Svezia 40
CZ - Repubblica Ceca 28
TR - Turchia 27
GB - Regno Unito 26
BE - Belgio 25
FI - Finlandia 24
CH - Svizzera 15
RO - Romania 13
IR - Iran 10
CA - Canada 9
RU - Federazione Russa 7
FR - Francia 6
JP - Giappone 6
NL - Olanda 6
PL - Polonia 6
AT - Austria 4
TG - Togo 4
EE - Estonia 3
EG - Egitto 3
EU - Europa 3
ES - Italia 2
HK - Hong Kong 2
BG - Bulgaria 1
BR - Brasile 1
CM - Camerun 1
CO - Colombia 1
IL - Israele 1
KR - Corea 1
MN - Mongolia 1
NG - Nigeria 1
RS - Serbia 1
Totale 5.890
Salva come PNG Salva come JPEG
Città #
Fairfield 716
Ashburn 489
Chandler 446
Woodbridge 346
Seattle 300
Houston 262
Wilmington 241
Cambridge 227
Ann Arbor 207
Boardman 145
Dearborn 115
Jacksonville 98
Princeton 76
Dublin 72
Beijing 71
Dong Ket 64
Singapore 56
Udine 51
New York 46
San Diego 39
Washington 34
Izmir 27
Martignacco 26
Redmond 26
Brno 25
Ogden 24
Brussels 22
Dallas 22
Des Moines 21
Los Angeles 19
Zurich 15
Phoenix 13
Falls Church 12
Nanjing 12
Norwalk 12
Hyderabad 11
Leawood 10
Naples 10
Arezzo 9
Timisoara 9
Trieste 9
Hefei 8
Milan 8
Munich 8
Augusta 7
Jinan 6
Rome 6
Warsaw 6
Codroipo 5
Cordenons 5
Kunming 5
Scafati 5
Simi Valley 5
Ardabil 4
Bovisio-Masciago 4
Edinburgh 4
Frankfurt am Main 4
Lomé 4
London 4
Menlo Park 4
Nanchang 4
Redwood City 4
Shenzhen 4
Tokyo 4
Zoppola 4
Cairo 3
Caserta 3
Fuzhou 3
Grafing 3
Hebei 3
Lappeenranta 3
Montréal 3
Münster 3
Nutley 3
Paris 3
Porcia 3
San Mateo 3
Shanghai 3
Tallinn 3
Toronto 3
Treviso 3
Wuhan 3
Bologna 2
Castelfranco Veneto 2
Cavaso del Tomba 2
Chengdu 2
Cincinnati 2
Clifton 2
Como 2
Curno 2
Fairborn 2
Fremont 2
Guangzhou 2
Hangzhou 2
Hong Kong 2
Innsbruck 2
Jinhua 2
Madrid 2
Monmouth Junction 2
Montreal 2
Totale 4.644
Salva come PNG Salva come JPEG
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 173
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 139
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 133
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 130
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 129
Pattern of metastasis and outcome in patients with breast cancer 127
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 122
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 119
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 114
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer 114
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 113
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach 111
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 108
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 108
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 108
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 106
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 103
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 100
Do platinum salts fit all triple negative breast cancers? 100
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 99
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 98
Determinants of Last-line Treatment in Metastatic Breast Cancer 96
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients 93
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle 91
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 91
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 91
Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 90
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 90
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 89
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 89
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 87
Complementary and alternative medicine in oncology [Le terapie alternative e complementari in oncologia] 86
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 85
null 84
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 83
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 82
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 81
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 80
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors 78
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 77
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. 75
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer 75
Risk factors and survival outcomes in patients with brain metastases from breast cancer 73
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 73
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 72
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation 71
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 68
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 64
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study 64
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer 62
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 62
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 58
Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis 55
Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology 54
Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models 54
Time to surgery after neoadjuvant chemotherapy for early breast cancer 52
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC 51
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer 50
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells 47
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) 47
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer 47
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 44
Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer 44
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 40
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 40
Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients 40
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 37
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 33
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 33
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer 33
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 31
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 31
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 28
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 25
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 24
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 24
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy 24
Landscape of circulating tumour DNA in metastatic breast cancer 21
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 21
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools 20
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 19
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 18
Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies 18
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study 16
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? 16
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? 15
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 14
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 14
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial 12
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 12
The use of serial circulating tumor DNA to detect resistance alterations in progressive metastatic breast cancer 12
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis 9
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach 7
Editorial: Altered expression of proteins in cancer: function and potential therapeutic targets, volume II 7
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases 7
The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives 7
Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer 7
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug–gene interactions 7
Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer 7
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer 6
Totale 6.194
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.229
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.229
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.521 0 0 60 214 140 216 188 176 206 173 89 59
2020/20211.306 52 131 91 229 114 72 85 143 81 69 108 131
2021/2022753 88 69 15 14 14 40 46 25 20 107 221 94
2022/2023928 87 101 28 124 99 212 3 72 125 10 48 19
2023/2024715 45 29 56 30 118 193 9 19 43 25 30 118
2024/2025305 130 158 17 0 0 0 0 0 0 0 0 0
Totale 6.273